Niridazole is a major antischistosomal drug that has been tested in several human trials with highly encouraging results (1, 14) . The drug acts as an anti-inflammatory agent (3) and strongly suppresses delayed-type hypersensitivity responses to schistosome egg proteins in the liver and lungs (13, 17) . Schistosomiasis is known to aggravate and prolong enteric and urinary salmonella infections in humans (11, 14, 16) . Niridazole treatment, by depressing the ability of the host to mount a cellular immune response to the bacteria-sensitizing antigens (3) , could increase the severity of the concurrent microbial infection in the schistosomal patient. Watson (18) recently reported that systemic niridazole treatment of Salmonella-infected mice did not exacerbate the disease. On the contrary, treatment of Salmonella typhimurium-infected mice with large doses of the drug actually reduced the level of splenic involvement compared with that of the normal controls. This unexpected effect seems to be due to the antibacterial activity shown by niridazole against S. typhimurium. When tested in vitro, the drug was growth inhibitory at a high dilution, suggesting that it was acting directly on the bacterial population in vivo (18) . The antibacterial and anti-inflammatory effects of this drug could thus be expected to offset each other; the results of this study suggest that this is indeed the case.
MATERIALS AND METHODS
Organisms. S. enteritidis NCTC 5694, S. gallinarum NCTC 9240, and S. typhimurium C5 have been described previously (2, 6) . S. typhi Ty2 and a hybrid of S. typhi-tYphimurium (10) and M. tuberculosis H37Rv were grown and stored as described elsewhere (4, 8, 9) . Drug treatment. Niridazole (Ambilhar) was generously donated by C. A. Brownly of CIBA Pharmaceuticals, Summit, N.J. Because the drug has a relatively low solubility in water, 10 mg (dry weight) had to be suspended in 1 ml of distilled water and shaken at 37 C for 2 h. The continuously stirred suspension was then introduced into specific-pathogen-free CD-1 mice intragastrically (5 developed to the infecting bacteria. A single dose of 100 mg of drug per kg, administered 1 day before challenge, reduced the size of the liver and spleen counts 10-fold compared with the controls but could not affect the subsequent immune response (Fig. 1) . None of the treated mice died, but two of five controls were dead by day 6.
Mycobacterial infections. Treatment of normal mice with 10 mg of niridazole per kg every other day for 15 days had little effect on the growth of either the BCG or H37Rv populations in the lungs, liver, or spleen compared with the control growth curves (shown in the accompanying paper) ( Fig. 2 and 3; reference 4 ). An immune response was normally seen about day 14 in untreated mice (7), but there was no sign of an immune decline in viable counts for M. tuberculosis H37Rv (Fig. 2) . The level of delayed hypersensitivity observed on day 14 was also 50% lower than expected, but, at the niridazole concentrations used in this study, tuberculin hypersensitivity was never completely suppressed. After the cessation of drug treatment on the 14th day of the mycobacterial infection, there was an obvious increase in tuberculin hypersensitivity over the next 7 days, and this event coincided with the emerging immune decline in the bacterial counts seen in the spleens and lungs of these mice (Fig. 2) . None of the infected mice died during the experimental period.
Salmonella infections. Treatment of mice with niridazole at either 10 or 100 mg per kg of body weight, given every other day, markedly depressed the growth of the S. enteritidis populations in both the liver and spleen. The effectiveness of a 1.0-mg dose per kg of body weight was debatable, but there was no question that the 10-mg and particularly the 100-mg dose per kg reduced growth of the Salmonella population significantly (P < 0.01) when compared with that seen in the control animals after 4 to 6 days (Fig. 3) Table 1 ). The MIC data clearly explain the relatively poor growth seen in the S. enteritidis-challenged mice receiving repeated doses of 100 mg of niridazole per kg of body weight (Fig. 4) . DISCUSSION Niridazole has a powerful antischistosomal effect even when tested at very small doses. The immunosuppressive effects of the drug (12) were expected to have some influence on the development of a concurrent salmonellosis. The present study makes it clear, however, that any immunosuppressive action (at least at dosages up to 100 mg/kg) was countered by a considerable antibacterial activity by niridazole on the Salmonella population in vivo. Watson (18) ORAL S. ENTERITIDIS enteritidis) was introduced intragastrically into mice that were then treated every other day with 10 mg of niridazole per kg of body weight, the liver and spleen counts increased after a lag of 4 to 6 days; the maximum in vivo population was about one-tenth of that seen in the sublethally infected normal controls (Fig. 4) ; this difference was significant (P < 0.02). The reduction in viable counts in the treated group was similar to that seen with this dosage level in the intravenously challenged mice (Fig. 3) . The treated mice still developed an immune response on day 9 of the oral challenge and were 14 , but by day 21 (6 days after stopping treatment) levels of hypersensitivity were back to those seen in the normal controls. The disappointingly small effect of niridazole treatment on the level of cellular hypersensitivity compared with that reported by others (12, 13) may have been due to differences in the dosages used. Attempts to prolong immunosuppression by the use of larger doses of drug over the first 15-day period of the infection were largely unsuccessful, although it is apparent that the normal mouse can tolerate doses of up to 600 mg per kg of body weight (18) . There seemed little point, however, in pursuing the present study into dosage ranges beyond those normally used in human trials (1, 15) .
